Robert Gunning
Patrimonio netto: - $ in data 31/08/2026
Patrimonio netto: - $ in data 31/08/2026
Robert W.
Gunning is currently Principal Accounting Officer, VP & Controller at NewAmsterdam Pharma Co. NV since 2026.
Formerly, Mr. Gunning was Controller at Altimmune, Inc. in 2026 and Vice President-Finance & Controller at Y-mAbs Therapeutics, Inc. from 2022 to 2026.
Mr. Gunning completed undergraduate education at Pace University.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 01/09/2026 | 0 ( -.--% ) | - $ | 31/08/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| FRAZIER LIFESCIENCES ACQUISITION CORPORATION | Comptroller/Controller/Auditor | 10/08/2026 |
| Società | Posizione | Fine |
|---|---|---|
| ALTIMMUNE, INC. | Comptroller/Controller/Auditor | 01/07/2026 |
| YMAS THER | Comptroller/Controller/Auditor | 01/04/2026 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 4 |
|---|---|
Pace University
Pace University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Y-mAbs Therapeutics, Inc.
Y-mAbs Therapeutics, Inc. BiotechnologyHealth Technology Develops radioimmunotherapy and antibody-based oncology therapies for treating cancer | Health Technology |
Altimmune, Inc.
Altimmune, Inc. BiotechnologyHealth Technology Develops biopharmaceuticals | Health Technology |
NewAmsterdam Pharma Co. NV
NewAmsterdam Pharma Co. NV Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that researches, develops, manufactures and commercializes transformative therapies for cardio-metabolic diseases | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale